Name: Abamune L
Brand: Cipla
SKU: Abamune L
Availability: InStock

💊 Abamune L — dual NRTI combination by Cipla. Generic alternative to Epzicom® for HIV-1 treatment.

📋 Product Overview

🧬 Active IngredientsAbacavir 600mg + Lamivudine 300mg

💊 IndicationHIV-1 Infection (First-line ART component for adults/adolescents ≥40kg)

🇺🇸 US BrandEpzicom®

🏭 ManufacturerCipla Ltd.

📦 Packaging30 tablets in HDPE bottle

💪 Strength600mg/300mg per tablet

🚚 Delivery Time7–14 days (Worldwide)

⚙️ Introduction to Abamune L

Abamune L by Cipla combines two nucleoside reverse transcriptase inhibitors (NRTIs) in a single tablet:

🧬 Abacavir 600mg — Guanosine analog requiring mandatory HLA-B*5701 screening
🛡️ Lamivudine 300mg — Cytidine analog with activity against both HIV and HBV

Approved for HIV-1 treatment in patients ≥40kg, this 30-tablet bottle offers once-daily dosing, renal safety (no dose adjustment needed), and simplifies ART regimens when combined with a third agent like Dolutegravir.

⚠️ Critical Safety Warnings — Black Box Warnings:

Fatal hypersensitivity reactions — in HLA-B*5701 positive patients. Mandatory screening required before initiation.
Increased myocardial infarction risk — in patients with existing cardiovascular risk factors.

💊 Dosage & Indications

💉 Indication	🧪 Dosage	⏱️ Frequency	💡 Notes
*Adults ≥40kg (HLA-B5701-)**	1 tablet	Once daily	With/without food
Adolescents (25-39kg)	Not recommended	–	Use separate formulations
Renal Impairment	Safe down to eGFR ≥15	–	Preferred over TDF
HBV Coinfection	Add HBV-active agent	–	Lamivudine has partial HBV activity

⚠️ Side Effects, Storage & Warnings

❗ Common Side Effects

Nausea (23%)
Headache (15%)
Fatigue (12%)

🚫 Life-Threatening Risks

Hypersensitivity reaction (fever, rash, multi-organ failure)
Myocardial infarction (in high-risk patients)
Lactic acidosis

❄️ Storage: 15–30°C; keep bottle tightly closed (desiccant included).

⚠️ Critical Warnings:

Contraindicated without confirmed HLA-B*5701 negative status
Discontinue permanently if hypersensitivity suspected
Monitor cardiovascular risk factors annually

🌍 Global Availability & Shipping

🌎 Region	📦 Shipping	💵 Price (30-tablet bottle)	📜 Prescription
🇺🇸 USA	✅ Yes	$50–$85	Required
🇬🇧 UK	✅ Yes	£40–£70	Required
🇦🇺 Australia	✅ Yes	AUD 70–110	Required

🔗 Related Antiretroviral Alternatives

💊 Product Name	🏭 Manufacturer	🔗 Link
Tenof-EM (Tenofovir/Emtricitabine)	Hetero	Tenof-EM
Tavin-L (Lamivudine/Tenofovir)	Cipla	Tavin-L
Viraday (Efavirenz/FTC/TDF)	Cipla	View →
Taffic (Bictegravir/TAF/FTC)	Hetero	View →
Doluteg-L (Dolutegravir/Lamivudine)	Emcure	Doluteg-L
Covihope-D (Dolutegravir/Ritonavir)	Hetero	Covihope-D

🩺 Hypersensitivity Reaction Protocol

Symptom Onset	Action
Within 6 weeks	Permanent discontinuation
Fever + GI symptoms	ER visit + corticosteroids
Respiratory distress	Epinephrine + oxygen support

❤️ Cardiovascular Monitoring

Parameter	Frequency	Action Threshold
Blood Pressure	Quarterly	>140/90 mmHg
Lipid Panel	Annual	LDL >160 mg/dL
ECG (if high risk)	Baseline	ST-segment changes

📦 Bottle Specifications

Amber HDPE bottle with child-resistant cap
Tablet ID: “ABL” engraving
Hypersensitivity warning card included

⚠️ Drug Interactions

Concomitant Drug	Risk	Action
Ribavirin	↑ Lactic acidosis risk	Avoid concurrent use
Ethanol	↑ Abacavir levels	Limit alcohol intake
Methadone	No interaction	Safe for MAT patients

🧬 HLA-B*5701 Screening Protocol

Test before first prescription
Document negative result in medical record
Never rechallenge if reaction suspected

📚 External Medical References

🩺 Dr. Neha Patel, HIV Specialist
“Abamune L’s once-daily convenience is offset by cardiovascular risks. For patients with cardiac history, Tenofovir-based regimens are safer. Always verify HLA-B*5701 status – Cipla includes a warning card in every bottle; educate patients to carry it.”

📺 Educational video: Understanding dual NRTI therapy and hypersensitivity screening

⚠️ Disclaimer

This information is not medical advice. Use under physician supervision. Cipla’s Abamune L carries black-box warnings for fatal hypersensitivity reactions. Mandatory HLA-B*5701 screening required before initiation. Discontinue permanently if hypersensitivity suspected.

🔐 Discreet Packaging • 💳 Multiple Payment Options • 📦 Guaranteed Reshipment • 🌍 Worldwide Shipping